Document Detail

Acute recurrent diverticulitis is prevented by oral administration of a polybacterial lysate suspension.
MedLine Citation:
PMID:  15722985     Owner:  NLM     Status:  MEDLINE    
AIM: The main cause of acute diverticulitis is the abnormal accumulation of fecal bacteria within the diverticular lumen, leading to a balancing between normal probiotic microflora and pathogenic species; Gram negative Entero-bacteriaceae, mainly Escherichia coli and Proteus spp, are the genders that usually cause the disease-related symptoms, due to their ability to adhere to intestinal mucosa. The intestine is well known as the largest human lymphoepithelial organ and daily produces more antibodies, mainly secretory IgAs, than do all other lymphoid tissues. IgAs have different immune and anti-inflammatory properties. The aim of this study was to verify the efficacy of an oral immunostimulant highly-purified, polymicrobial lysate in the prevention of recurrent attacks of diverticulitis and in the improvement of symptoms.
METHODS: The study was carried out on 83 consecutive patients suffering from recurrent symptomatic acute diverticulitis and with at least 2 attacks in the previous year; patients were randomly assigned to receive (group A) an oral polybacterial lysate suspension or to a no-treatment clinical follow-up as controls (group B).
RESULTS: A total of 76 patients (41 in group A and 35 in group B) terminated the study period. the sums of the scores for symptoms, reported on day schedules, were calculated and examined by means of ANOVA statistical analysis. Statistical differences between group A vs group B were recorded after 1 month (p<0.05) and 3 months (p<0.01) of treatment with the oral polybacterial lysate suspension.
CONCLUSIONS: Our data suggest that the administration of an oral enterovaccine for the prophylaxis of recurrent diverticulitis is effective and well tolerated, probably due to a direct stimulation of IgA-mediated mucosal defences.
L Dughera; A M Serra; E Battaglia; D Tibaudi; M Navino; G Emanuelli
Related Documents :
4028555 - Methicillin-resistant staphylococcus aureus osteomyelitis.
12655535 - Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutr...
16138425 - The role of vancomycin in the persistence or recurrence of staphylococcus aureus bacter...
9835495 - Ambulatory treatment of multidrug-resistant staphylococcus-infected orthopedic implants...
24203805 - Changes in prostaglandin levels in patients undergoing femtosecond laser-assisted catar...
22509125 - Maxillary protraction in adult cleft lip and palate by a rigid external distraction dev...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Minerva gastroenterologica e dietologica     Volume:  50     ISSN:  1121-421X     ISO Abbreviation:  Minerva Gastroenterol Dietol     Publication Date:  2004 Jun 
Date Detail:
Created Date:  2005-02-21     Completed Date:  2005-03-11     Revised Date:  2012-06-22    
Medline Journal Info:
Nlm Unique ID:  9109791     Medline TA:  Minerva Gastroenterol Dietol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  149-53     Citation Subset:  IM    
Digestive Motility and Endoscopy Unit, Department of Clinical Physiopathology, University of Turin, Turin, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Adjuvants, Immunologic / administration & dosage*
Administration, Oral
Analysis of Variance
Anti-Infective Agents / administration & dosage,  therapeutic use
Bacterial Vaccines / administration & dosage*
Cell Extracts / administration & dosage*
Chi-Square Distribution
Ciprofloxacin / administration & dosage,  therapeutic use
Diverticulitis / diagnosis,  drug therapy,  immunology,  microbiology,  prevention & control*,  therapy
Diverticulitis, Colonic / diagnosis,  drug therapy,  immunology,  microbiology,  prevention & control,  therapy
Follow-Up Studies
Gastrointestinal Agents / administration & dosage,  therapeutic use
Injections, Intravenous
Intestinal Mucosa / immunology
Middle Aged
Rifamycins / administration & dosage,  therapeutic use
Time Factors
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Anti-Infective Agents; 0/Bacterial Vaccines; 0/Broncho-Vaxom; 0/Cell Extracts; 0/Gastrointestinal Agents; 0/Rifamycins; 85721-33-1/Ciprofloxacin; 88747-56-2/rifaximin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  What do heartburn sufferers expect from proton pump inhibitors when prescribed for the first time?
Next Document:  Intestinal permeability assessment before and after ileal pouch-anal anastomosis.